Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Carvedilol

CAS No.

72956-09-3

Innovator/marketer

Coreg

Polymorphic form

Form II

Therapeutic Area

Cardiovascular system

Status

Commercial

EU DMF readiness

US DMF readiness

017060

CEP

Other documentation

Korean DMF

Drug description:

Carvedilol is a carbazole derivative acts as anti-hypertensive agent.
Carvedilol is indicated for the management of essential hypertension. It is also indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction. Carvedilol is also indicated for the treatment of tachycardiac atrial fibrillation.
It is formulated as tablets or film coated tablets for oral route of administration.

Mechanism of action:

Carvedilol acts as a nonselective beta-adrenoceptor blocking agent and as an alpha 1-adrenoceptor blocker. It's beta-adrenergic receptor (beta-1 and beta-2 adrenergic receptors) blocking ability decreases the heart rate, myocardial contractility, and myocardial oxygen demand. Carvedilol also decreases systemic vascular resistance via its alpha adrenergic (alpha-1) receptor blocking properties. Carvedilol and its metabolites also prevent OH- radical-induced decrease in sarcoplasmic reticulum Ca2+-ATPase activity. Therefore, carvedilol and its metabolites may be beneficial in chronic heart failure by preventing free radical damage.

DISCLAIMER
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).

OK